Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Hepatitis C (HCV) is associated with several extrahepatic manifestations, and estimates of the hospitalization burden related to these comorbidities are still limited. The aim of this study is to quantify the hospitalization risk associated with comorbidities in an Italian cohort of HCV-infected patients and to assess which of these comorbidities are associated with high hospitalization resource utilization.
Methods: Individuals aged 18 years and older with HCV-infection were identified in the Abruzzo's and Campania's hospital discharge abstracts during 2011-2014 with 1-year follow-up. Cardio-and cerebrovascular disease, diabetes and renal disease were grouped as HCV-related comorbidities. Negative binomial models were used to compare the hospitalization risk in patients with and without each comorbidity. Logistic regression model was used to identify the characteristics of being in the top 20% of patients with the highest hospitalization costs (high-cost patients).
Results: 15,985 patients were included; 19.9% had a liver complication and 48.6% had one or more HCV-related comorbidities. During follow-up, 36.0% of patients underwent at least one hospitalization. Liver complications and the presence of two or more HCV-related comorbidities were the major predictors of hospitalization and highest inpatient costs. Among those, patients with cardiovascular disease had the highest risk of hospitalization (Incidence Rate Ratios = 1.42;95%CI:1.33-1.51) and the highest likelihood of becoming high-cost patients (Odd Ratio = 1.37;95%CI:1.20-1.57).
Conclusion: Beyond advanced liver disease, HCV-related comorbidities (especially cardiovascular disease) are the strongest predictors of high hospitalization rates and costs. Our findings highlight the potential benefit that early identification and treatment of HCV might have on the reduction of hospitalization costs driven by extrahepatic conditions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619769 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0219396 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Hepatitis C Treatment Initiation During Hospitalization for People Who Use Drugs: A Narrative Review of the Literature.
Open Forum Infect Dis
June 2025
Section of Addiction Medicine, Division of General Internal Medicine and Geriatrics, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
People who use drugs (PWUD) are increasingly acquiring and transmitting hepatitis C virus (HCV) and being admitted to the hospital for often costly non-HCV-related conditions. Traditionally, treatment of HCV has been deferred to the outpatient setting. However, outpatient HCV follow-up can be an arduous process to navigate with resultant gaps in care, especially for PWUD with numerous complex psychosocial and medical comorbidities.
View Article and Find Full Text PDFRisk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon.
Aliment Pharmacol Ther
April 2025
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Background: Few studies have examined the risk of de novo hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)-infected patients with cirrhosis who received interferon (IFN)-free direct-acting antiviral (DAA) therapy relative to patients who received IFN-containing therapy or remained untreated.
Aims: To estimate the risk of de novo HCC with DAA treatment in cirrhotic HCV patients compared to no anti-HCV treatment and those treated with IFN-based therapy.
Methods: We identified patients with chronic HCV infection and compensated cirrhosis in the US Department of Veterans Affairs healthcare system treated with IFN (2005 to 2013) or DAAs (2013 to 2017).
Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia.
Lancet Reg Health West Pac
October 2024
The Kirby Institute, UNSW Sydney, Australia.
Article Synopsis
- A study in NSW, Australia analyzed hepatitis B (HBV) and C (HCV) notifications from 1995 to 2022, linking them to hospital and mortality records to assess liver disease outcomes.
- Results showed significant reductions in decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality, especially during the viral hepatitis elimination era (2015-2022) for HCV.
- The findings suggest that, while HBV-related improvements started earlier, HCV-related declines were more pronounced during the elimination era, indicating targets for reducing liver-related mortality were largely met by 2022.
Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.
Aliment Pharmacol Ther
February 2024
Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Background: Since the inception of the interferon-free direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection, guidelines as to who should receive this potentially curative treatment have evolved. Treatment with DAAs is now considered for all patients except for those considered moribund.
Aim: To determine the DAA treatment rate for patients with HCV-related hepatocellular carcinoma (HCC).
Recent updates in the diagnosis and management of cryoglobulinemic vasculitis.
Expert Rev Clin Immunol
November 2023
Rheumatology Unit, Department of Medicine, University of Udine, Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC), Udine, Italy.
Article Synopsis
- Cryoglobulinemic vasculitis (CV), also known as mixed cryoglobulinemic syndrome (MCS), is a complex autoimmune disease that affects small blood vessels and presents various clinical symptoms, making treatment difficult for doctors.!
- A thorough review of current practices shows that accurate diagnosis and individual treatment plans are essential and should consider factors like disease severity and associated health issues, with antiviral agents and B-cell-targeted therapies being primary treatment options.!
- MC is unique among autoimmune diseases because its causes, mainly linked to infections, are relatively well understood, presenting opportunities for further research, but challenges remain in treating resistant cases, particularly those related to other autoimmune disorders or labeled as 'essential' CV.!